ERA® is a diagnostic test patented by Igenomix in 2009

3 in every 10 patients have a displaced WOI

ERA analyzes 248 genes related to endometrial receptivity

pET | Personalized Embryo Transfer

<table>
<thead>
<tr>
<th></th>
<th>RECEPTIVE</th>
<th>CORRECTION</th>
<th>TOTAL</th>
</tr>
</thead>
<tbody>
<tr>
<td>NUMBER OF PET PERFORMED</td>
<td>215</td>
<td>297</td>
<td>512</td>
</tr>
<tr>
<td>IMPLANTATION RATE</td>
<td>56.3% (166/295)</td>
<td>58.2% (216/371)</td>
<td>57.4% (382/666)</td>
</tr>
<tr>
<td>PREGNANCY RATE</td>
<td>73% (157/215)</td>
<td>72.7% (216/297)</td>
<td>72.9% (373/512)</td>
</tr>
<tr>
<td>BIOCHEMICAL PREGNANCY</td>
<td>9.6% (15/157)</td>
<td>10.6% (23/216)</td>
<td>10.2% (38/373)</td>
</tr>
<tr>
<td>MISCARRIAGE</td>
<td>11.5% (18/157)</td>
<td>12% (26/216)</td>
<td>11.8% (44/373)</td>
</tr>
<tr>
<td>ECCOTIC</td>
<td>0.6% (1/157)</td>
<td>0.5% (1/216)</td>
<td>0.5% (2/373)</td>
</tr>
<tr>
<td>ONGOING / PREGNANCY</td>
<td>78.3% (123/157)</td>
<td>76.9% (166/216)</td>
<td>77.5% (289/373)</td>
</tr>
<tr>
<td>ONGOING / PET</td>
<td>57.2% (123/215)</td>
<td>55.9% (166/297)</td>
<td>56.4% (289/512)</td>
</tr>
</tbody>
</table>

On behalf of the ERA consortium
Personalized embryo transfer (pET) according to ERA®

Indicated for recurrent implantation failure (RIF)

Days with ESTRADIOL VALERATE

Days with PROGESTERONE

Menstruation

P4 administration

VAGINAL ULTRASOUND
Triple layer 6.5 mm
Endogenous P4 < 1 ng/ml

+ 55,000 patients
+ 60 countries
More than 1,500 clinics

June 2019
Why choose Igenomix ERA test?

- ERA is backed by 33 publications 29 from Igenomix and 4 external publications.

- Randomized study in progress to assess its applicability in patients without any prior ART.
  (ClinicalTrials.gov Identifier: NCT01954758)

- Algorithms based on machine learning technologies.

- ERA allows clinicians to identify transition phases with 12 hours shifts.
When is a second biopsy needed?

90% of cases don't need a second biopsy. The second biopsy is only required under two circumstances:

- Patients with a "Pre-receptive 2 days" result.
- Patients with a "Post-receptive" result.

In case of proliferative, non-informative, non-valid RNA or insufficient RNA result, the test should be repeated.